Patterns of left ventricular hypertrophy in essential hypertension: Should echocardiography guide the pharmacological treatment?

International Journal of Cardiology

Volumn 124, Issue 2, 2008, Pages 134-138

  Dávila, Diego F ^a   Donis, Jose H ^a   Odreman, Rodolfo ^a   Gonzalez, Maite ^a   Landaeta, Agustin ^a  

^a UNIVERSIDAD DE LOS ANDES   (Venezuela)

Author keywords

Essential hypertension; Left ventricular geometry; Left ventricular hypertrophy; Neurohormonal activation; Pharmacological treatment

Indexed keywords

ALDOSTERONE; ATENOLOL; CATECHOLAMINE; LOSARTAN; RENIN;

BLOOD VOLUME; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEMODYNAMICS; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW; VASCULAR RESISTANCE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; VENTRICULAR REMODELING;

EID: 38649140465     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.01.089     Document Type: Review

References (48)

1. The National Heart, Lung and Blood Institute Working Group on Future Directions in Hypertension Treatment Trials. Major clinical trials of hypertension. What should be done next?. Hypertension 46 (2005) 1-6
2. Chobanian A.V., Bakris G.L., Black H.R., et al., and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 42 (2003) 1206-1252
3. Laragh J.H., and Sealy J.E. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and evaluating ALLHAT. Am J Hypertens 16 (2003) 407-415
4. de Simone G., DiLorenzo L., Constantino G., Moccia D., Buonissimo S., and de Vittis O. Hemodynamic hypertrophied left ventricular patterns in systemic hypertension. Am J Cardiol 60 (1987) 1317-1321
5. Ganau A., Devereux R.B., Roman M.J., et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19 (1992) 1550-1558
6. Schmieder R.E., Schobel H.P., and Messerli F.H. Central blood volume: a determinant of early cardiac adaptation in arterial hypertension?. J Am Coll Cardiol 26 (1995) 1692-1698
7. Bella J.N., Watchell K., Palmieri V., et al. Relation of left ventricular geometry and function to systemic hemodynamics: the LIFE study. J Hypertens 19 (2001) 127-134
8. Jones E.C., Devereux R.B., O'Grady M.J., et al. Relation of hemodynamic volume load to arterial and cardiac size. J Am Coll Cardiol 29 (1997) 1303-1310
9. Muscholl M.W., Schunkert H., Muders F., et al. Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension. Am Heart J 135 (1998) 58-66
10. du Cailar G., Pasquie J.L., Ribstein J., and Mimran A. Left ventricular adaptation to hypertension and plasma renin activity. J Human Hypertens 14 (2000) 181-188
11. Yingxin P., Jiang S., Xiaoyong Q., et al. Regulation of the catecholamine β-adrenergic system in ventricular remodeling of hypertension. Jpn Heart J 45 (2004) 285-296
12. Gould K.L., Lipscomb K., Hamilton G.W., and Kennedy J.W. Relation of left ventricular shape, function and wall stress in man. Am J Cardiol 34 (1974) 627-634
13. Dequatro V., and Feng M. The sympathetic nervous system: the muse of hypertension. J Human Hypertens 16 S1 (2002) S64-S69
14. Esler M., Rumantir M., Kaye D., et al. Sympathetic nerve biology in essential hypertension. Clin Exp Pharmacol Physiol 28 (2001) 986-989
15. Flaa A., Mundal H.H., Eide I., Kjeldsen S., and Rostrup M. Sympathetic activity and cardiovascular risk factors in young men in the low, normal and high blood pressure ranges. Hypertension 47 (2006) 396-402
16. Mann S. Neurogenic essential hypertension revisited: the case for increased clinical and research attention. Am J Hypertens 16 (2003) 881-888
17. Goldstein D.S., and Lake C.R. Plasma norepinephrine and epinephrine levels in essential hypertension. Fed Proc 43 (1984) 57-61
18. DeQuatro V., and Chan S. Raised plasma catecholamines in some patients with primary hypertension. Lancet 1 (1972) 806-809
19. Schroeder A.P., Sihm I., Morn B., Thygesen K., Pedersen E.B., and Lederballe O. Influence of humoral and neurohumoral factors on cardiovascular hypertrophy in untreated essential hypertensives. Am J Hypertens 9 (1996) 207-215
20. Brown B., and Hall A.S. Renin-angiotensin system modulation: the weight of evidence. Am J Hypertens 18 (2005) 127S-133S
21. Alderman M.H., Cohen H.W., Sealy J.E., and Laragh J.H. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic in most elderly patients. Am J Hypertens 17 (2004) 1-7
22. Ibrahim M.M. RAAS inhibition in hypertension. J Human Hypertens 20 (2006) 101-108
23. Laragh J.H., and Sealy J.E. Renin-sodium profiling: why, how and when in clinical practice. New Engl J Med 286 (1972) 441-449
24. Buhler F.R., Laragh J.H., Vaughan Jr. E.D., Brunner H.R., Gavras H., and Baer L. Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renovascular and malignant hypertension. Am J Cardiol 32 (1973) 511-522
25. Vaughan Jr. E.D., Laragh J.H., Gavras I., et al. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. Am J Cardiol 32 (1973) 523-532
26. Iwashima Y., Horio T., Kuroda S., Takishita S., and Kawano Y. Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension. Hypertens Res 25 (2002) 49-56
27. Nishikimi T., Yoshihara F., Morimoto A., et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 28 (1996) 22-30
28. Yasumoto K., Takata M., Ueno H., Tomita S., Tomoda F., and Inoue H. Relation of plasma brain and atrial natriuretic peptides to left ventricular geometric patterns in essential hypertension. Am J Hypertens 12 (1999) 921-924
29. Davila D.F., Nunez T.J., Odreman R., and de Davila C.A. Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications. Int J Cardiol 101 (2005) 343-346
30. Davila D.F., Donis J.H., Bellabarba G., Torres A., Casado J., and Mazzei de Dávila C.A. Cardiac afferents and neurohormonal activation in congestive Herat failure. Med. Hypotheses 54 (2000) 242-253
31. Hunter J.J., and Chien K.R. Signaling pathways for cardiac hypertrophy and failure. New Eng J Med 341 (1999) 1276-1286
32. Akhter S.A., Luttrell L.M., Rockman H.A., Iaccarino G., Leftkowitz R.J., and Koch W.G. Targeting the receptor-Gq interface to inhibit in vivo pressure myocardial hypertrophy. Science 280 (1998) 574-577
33. Chien K.R. Stress pathways and failure. Cell 98 (1999) 555-558
34. Deveraux R.B., and Krauser D.G. Ventricular hypertrophy and hypertension. Herz 31 (2006) 305-316
35. Wachtell K., Dahlof B., Rokkedal J., et al. Change in left ventricular geometry pattern after one year of antihypertensive treatment: The Losartan intervention for end point reduction in hypertension (LIFE) study. Am Heart J 144 (2002) 1057-1064
36. Gerdts E., Roman M.J., Palmieri V., et al. Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). J Human Hypertens 18 (2004) 417-422
37. Barrios V., Calderón A., Tomás J.P., et al. Echocardiographic left ventricular hypertrophy regression induced by candesartan in clinical practice. The VIPE study. J Hypertens 23 suppl 2 (2005) S39
38. Taniguchi I., Kawai M., Date T., et al. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circ J 70 (2006) 995-1000
39. Li F., Wang X., Yi X.P., and Gerdes A.M. Structural basis of ventricular remodeling: role of the myocyte. Curr Heart Fail Rep 1 (2004) 5-8
40. Tamura T., Onodera T., Said S., and Gerdes A.M. Correlation of myocyte lengthening to chamber dilation in the spontaneously hypertensive heart failure (SHHF) rat. J Mol Cell Cardiol 30 (1998) 2175-2181
41. Onodera T., Tamura T., Said S., McCune S.A., and Gerdes A.M. Maladaptive remodeling of cardiac myocyte shape begins long before failure in hypertension. Hypertension 32 (1998) 753-757
42. Gerdes A.M., Onodera T., Wang X., and McCune S.A. Myocyte remodeling during the progression to failure in rats with hypertension. Hypertension 28 (1996) 609-614
43. Gerdes A.M., Kellerman S.E., Moore J.A., et al. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation 86 (1992) 426-430
44. Tamura T., Said S., Harris J., Lu W., and Gerdes A.M. Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. Circulation 102 (2000) 253-259
45. Zafeiridis A., Jeevanandam V., Houser S.R., and Margulies K.B. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 98 (1998) 656-662
46. Martina B., Nordmann A., Dieterle T., et al. Impact of baseline echocardiography on treatment outcome in primary care patients with newly detected arterial hypertension: a randomized trial. Am J Hypertens 19 (2006) 1150-1155
47. Kizer J.R., and Deveraux R.B. Regression of left ventricular hypertrophy: lodestar to stroke prevention in the treatment of hypertension. Am J Hypertens 19 (2006) 439-442
48. Bella J.N., and Deveraux R.B. Is echocardiography essential in the management of newly diagnosed hypertension?. Am J Hypertens 19 (2006) 1156-1157